Picture of Medicenna Therapeutics logo

MDNA Medicenna Therapeutics Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-11.04%
3m-17.57%
6m-44.33%
1yr-62.91%
Volume Change (%)
10d/3m-2.5%
Price vs... (%)
52w High-68%
50d MA-13.31%
200d MA-39.15%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-85.21%
Return on Equity-97.22%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202631st Mar 2027
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2026 / 2027

Blurred out image of Medicenna Therapeutics EPS forecast chart

Profile Summary

Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.

Directors

Last Annual
March 31st, 2025
Last Interim
March 31st, 2025
Incorporated
February 2nd, 2015
Public Since
July 13th, 2015
No. of Employees
18
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
ca flag iconToronto Stock Exchange
Shares in Issue
83,380,737

MDNA Share Price Performance

Upcoming Events for MDNA

Q1 2026 Medicenna Therapeutics Corp Earnings Release

Medicenna Therapeutics Corp Annual Shareholders Meeting

Q2 2026 Medicenna Therapeutics Corp Earnings Release

Similar to MDNA

Picture of Appili Therapeutics logo

Appili Therapeutics

ca flag iconToronto Stock Exchange

Picture of Avicanna logo

Avicanna

ca flag iconToronto Stock Exchange

Picture of Briacell Therapeutics logo

Briacell Therapeutics

ca flag iconToronto Stock Exchange

Picture of Cardiol Therapeutics logo

Cardiol Therapeutics

ca flag iconToronto Stock Exchange

Picture of COSCIENS Biopharma logo

COSCIENS Biopharma

ca flag iconToronto Stock Exchange

FAQ